
    
      The aims of our study are:

        1. to describe the treated population at initiation of treatment,

        2. to evaluate clinical parameters during the year before Ivacaftor was started, at
           initiation of treatment and during at least one year of treatment, until June 2014.

        3. to evaluate the tolerance and safety of this treatment.
    
  